The integration of nanoparticles with classical drugs to create biocompatible delivery platforms for the treatment of cardiovascular diseases can make a major impact on patient welfare.
Traditional drug delivery systems are not selective and induce severe collateral damage to surrounding non-diseased cells and tissues. Nanoparticles, however, can be bio-conjugated with antibodies to encapsulate cardiovascular drugs, gaseous molecules and biomolecules to selectively deliver them in a safe, targeted and cost-effective manner.
This book provides in-depth and insightful discussion on the mechanistic, pre-clinical and clinical applications of nanomedicine in cardiovascular disease. It not only discusses core chemical concepts via the synthesis of novel nanotechnology-based drug formulations, but also covers the latest drug delivery advances including innovative therapeutic targets in cardiovascular lesions at an early, curable and reversible stage.
Written by experts in the field, students and researchers will find this book equally useful for understanding the trends and challenges of the clinical translation of cardiovascular nanomedicine.
Paga facilmente con carta, Klarna, Apple Pay o Google Pay. Non sei soddisfatto? Hai sempre 14 giorni per il rimborso. Leggi di più nei nostri termini. Per qualsiasi domanda, scrivici a hello@memmo.org.
Memmo rende lo studio più facile, ovunque tu sia nel mondo. Qui trovi i tuoi libri di testo e strumenti di studio intelligenti, tutto in un unico posto: riassunti, quiz, podcast e flashcard. E poi c'è Ted, il tuo compagno di studio che risponde a ogni tua domanda. Oltre 50.000 studenti studiano già qui: è stato creato per aiutarti a imparare più velocemente e a stressarti meno.